Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Avelumab in Genomically Defined Metastatic RCC
NCT04068831Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in metastatic renal cell carcinoma (mRCC), renal medullary carcinoma (RMC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2019; status: completed.
02
Drugs
talazoparib
03
Conditions
metastatic renal cell carcinoma (mRCC)renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT04068831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068831.